Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.87 USD | -10.21% |
|
-18.53% | -46.25% |
08/05 | Transcript : Raia Drogasil S.A., Q1 2024 Earnings Call, May 08, 2024 | |
07/05 | Raia Drogasil S.A. acquired remaining 15% stake in 4Bio Medicamentos S.A. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.88 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-46.25% | 7.85B | - | ||
+20.14% | 1.21B | - | ||
+7.72% | 281M | - | ||
+8.89% | 223M | - | - | |
-47.09% | 79.61M | C | ||
-32.11% | 65.01M | - | - | |
+32.57% | 63.45M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RADL3 Stock
- RADLY Stock
- Ratings Raia Drogasil S.A.